Get started
Author

Qingya Cui

Observed names: Cui, Qingya, Q Y Cui, Q. Cui, Qing-Ya Cui
ORCID: 0000-0002-5067-5650
Observed ORCID: 0000-0002-5067-5650
OpenAlex ID: A5037787108
CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
2021 · Qingya Cui, Chongsheng Qian, et al. · Journal of Hematology & Oncology · 123
PDF
Akt-mediated platelet apoptosis and its therapeutic implications in immune thrombocytopenia
2018 · Mengxing Chen, Rong Yan, et al. · Proceedings of the National Academy of Sciences · 69
PDF
Protein kinase A determines platelet life span and survival by regulating apoptosis
2017 · Lili Zhao, Jun Liu, et al. · Journal of Clinical Investigation · 65
PDF
Receptor-interacting protein kinase 3 promotes platelet activation and thrombosis
2017 · Yiwen Zhang, Jian Zhang, et al. · Proceedings of the National Academy of Sciences · 46
CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia
2022 · Xuanqi Cao, Haiping Dai, et al. · Experimental Hematology and Oncology · 39
PDF
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
2023 · Sining Liu, Xinyue Zhang, et al. · Blood Cancer Journal · 36
PDF
Single‐Cell Spatial Transcriptomics Unveils Platelet‐Fueled Cycling Macrophages for Kidney Fibrosis
2024 · Jun Liu, Bo Zheng, et al. · Advanced Science · 27
PDF
Differential Expression of MiR-106b-5p and MiR-200c-3p in Newly Diagnosed Versus Chronic Primary Immune Thrombocytopenia Patients Based on Systematic Analysis
2018 · Cheng Qian, Wenying Yan, et al. · Cellular Physiology and Biochemistry · 25
PDF
Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients
2023 · Yunju Ma, Haiping Dai, et al. · Experimental Hematology and Oncology · 23
PDF
Clinical and molecular insights into Glanzmann's thrombasthenia in China
2018 · L. Zhou, M. Jiang, et al. · Clinical Genetics · 21
Early T-Cell Precursor Acute Lymphoblastic Leukemia and T/Myeloid Mixed Phenotype Acute Leukemia Possess Overlapping Characteristics and Both Benefit From CAG-Like Regimens and Allogeneic Hematopoietic Stem Cell Transplantation
2021 · Sining Liu, Qingya Cui, et al. · Transplantation and Cellular Therapy · 19
Case report: CD38-directed CAR-T cell therapy: A novel immunotherapy targeting CD38- positive blasts overcomes TKI and chemotherapy resistance of myeloid chronic myeloid leukemia in blastic phase
2022 · Qingya Cui, Peiqi Liang, et al. · Frontiers in Immunology · 15
PDF
Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Acquires Superior CR Rate Than CD19 CAR-T Cells: A Case Controlled Study
2020 · Wei Cui, Xinyue Zhang, et al. · Blood · 12
Rituximab potentially improves clinical outcomes of CAR-T therapy for r/r B-ALL via sensitizing leukemia cells to CAR-T-mediated cytotoxicity and reducing CAR-T exhaustion
2024 · Yangzi Li, Qingya Cui, et al. · Cellular Oncology · 11
PDF
Inhibition of ferroptosis promotes megakaryocyte differentiation and platelet production
2022 · Baoquan Song, Wenjing Miao, et al. · Journal of Cellular and Molecular Medicine · 11
Modified immunosuppressive therapy with porcine antilymphocyte globulin plus delayed cyclosporine A in children with severe aplastic anemia
2017 · Qingya Cui, Pingping Sha, et al. · International Journal of Hematology · 9
Case Report: A Case of Acute T Lymphoblastic Leukemia With Mixed Infection of Lethal Invasive Mucormycosis and Multi-Drug Resistant Bacteria
2022 · Qingya Cui, Haiping Dai, et al. · Frontiers in Medicine · 8
PDF
Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy
2022 · Jingxian Gu, Sining Liu, et al. · Frontiers in Immunology · 8
Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Obtains Superior CR Rate Than Single CD19 CAR-T Cells Infusion As Well As Sequential CD19 and CD22 CAR-T Cells Infusion for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients
2021 · Sining Liu, Xinyue Zhang, et al. · Blood · 8
Successful treatment of a B/T MPAL patient by chemo-free treatment with venetoclax, azacitidine, and blinatumomab
2024 · Shaoyu Liu, Qingya Cui, et al. · Annals of Hematology · 7
PDF
Rituximab Improves Clinical Outcomes of CAR-T Therapy for r/r B-ALL Via Sensitizing Leukemia Cells to CAR-T-Mediated Cytotoxicity and Reducing CAR-T Exhaustion
2023 · Yangzi Li, Sining Liu, et al. · Blood · 7
Effective treatment with para-aminomethylbenzoic acid for chronic disseminated intravascular coagulation associated with aortic dissection
2014 · Qingya Cui, Tianqin Wu, et al. · Blood Coagulation & Fibrinolysis · 6
Unleashing the Power of CD19 CAR-T in Relapsed AML: Findings from a Prospective Single-Center Clinical Trial
2024 · Jia Yin, Qingya Cui, et al. · Blood · 5
PDF
Tandem CD19 / CD22 CAR T‐Cell Therapy as First‐Line Treatment for Adult Patients With High‐Risk Philadelphia Chromosome Negative B‐Cell Acute Lymphoblastic Leukemia
2025 · Mengyun Li, Qingya Cui, et al. · American Journal of Hematology · 4
PDF
Tandem CD19/CD22 Dual Targets CAR T-Cells Bridging Hematopoietic Stem Cells Transplantation Acquires Robust Remission for Relapsed and Refractory B Acute Lymphoblastic Leukemia Patients
2021 · Wei Cui, Xinyue Zhang, et al. · Blood · 4
Works count: 66
Citation count: 640
H-index: 12
I10-index: 15
Year
Topic
Type